

Barcelona, March 16th 2021

OTHER RELEVANT INFORMATION

Almirall has decided not to exercise its option right to acquire Bioniz Therapeutics Inc.

In accordance with the Spanish Securities Markets Law, Almirall, S.A. (“Almirall”) announces the following:

Following the 60 day data review period Almirall has decided not to exercise its option right to acquire Bioniz Therapeutics Inc.

Under the terms of the Option Agreement entered in January 2020, Almirall made an initial payment of \$15 million to Bioniz in exchange for an option to acquire all Bioniz outstanding shares. Following the decision not to exercise the option, there are no further payments required.

Yours sincerely,

Pablo Divasson del Fraile
Investor Relations Department
investors@almirall.com